Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 171Fallopian Tube Neoplasms 85Uterine Cervical Neoplasms 40Carcinoma, Ovarian Epithelial 28Endometrial Neoplasms 27Neoplasms 14Peritoneal Neoplasms 10Colorectal Neoplasms 9Brenner Tumor 9Breast Neoplasms 9Stomach Neoplasms 8Recurrence 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Carcinoma 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Carcinoma, Hepatocellular 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Ovarian Diseases 3Melanoma 3Glioblastoma 3Carcinoma, Renal Cell 3Vulvar Neoplasms 2Vaginal Neoplasms 2Vaccinia 2Uterine Neoplasms 2Urinary Bladder Neoplasms 2

Interventions

fluzoparib 1Paclitaxel 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Platinum-sensitive Relapsed Ovarian Cancer × Bevacizumab × Gynecologic × Clear all
NCT06446206 2024-06-06

Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer

The First Hospital of Jilin University

Phase 2 Not yet recruiting
22 enrolled
Gynecologic

Platinum-sensitive Relapsed Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡